To understand the time-course of viraemia and antibody responses to severe acute respiratory syndrome-associated coronavirus (SARS-CoV), RT-PCR and ELISA were used to assay 376 blood samples from 135 SARS patients at various stages of the illness, including samples from patients who were in their early convalescent phase. The results showed that IgM antibodies decreased and became undetectable 11 weeks into the recovery phase. IgG antibodies, however, remained detectable for a period beyond 11 weeks and were found in 100 % of patients in the early convalescent phase. SARS-CoV viraemia mainly appeared 1 week after the onset of illness and then decreased over a period of 1 month, becoming undetectable in the blood samples of the convalescent patients. At the peak of viraemia, viral RNA was detectable in 75 % of blood samples from patients who were clinically diagnosed with SARS 1 or 2 weeks before the test.


Article metrics loading...

Loading full text...

Full text loading...



  1. Drosten, C., Günther, S., Preiser, W. & 23 other authors ( 2003;). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348, 1967–1976.[CrossRef]
    [Google Scholar]
  2. Gao, G., Qiu, Y., Zhang, P. & 9 other authors ( 2003;). Investigation on SARS in Beijing volunteer blood donors. Chin J Blood Transfus 16, 223–226.
    [Google Scholar]
  3. Ksiazek, T. G., Erdman, D., Goldsmith, C. S. & 23 other authors ( 2003;). A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348, 1953–1966.[CrossRef]
    [Google Scholar]
  4. Lee, N., Hui, D., Wu, A. & 11 other authors ( 2003;). A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348, 1986–1994.[CrossRef]
    [Google Scholar]
  5. Li, G., Chen, X. & Xu, A. ( 2003;). Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 349, 508–509.[CrossRef]
    [Google Scholar]
  6. Ministry of Health ( 2003;). Discharge guideline for patients diagnosed as severe acute respiratory syndrome. People's Republic of China, release date 2003 05 03.
  7. Peiris, J. S. M., Lai, S. T., Poon, L. L. M. & 13 other authors ( 2003a;). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325.[CrossRef]
    [Google Scholar]
  8. Peiris, J. S. M., Chu, C. M., Cheng, V. C. & 13 other authors ( 2003b;). Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772.[CrossRef]
    [Google Scholar]
  9. Poon, L. L. M., Chan, K.H., Wong, O. K., Yama, W. C., Yuen, K. Y., Guan, Y., Lo, Y. M. D. & Peiris, J. S. M. ( 2003;). Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 28, 233–238.[CrossRef]
    [Google Scholar]
  10. Qin, E., Zhu, Q., Yu, M. & 44 other authors ( 2003;). A complete sequence and comparative analysis of a SARS-associated virus (isolate BJ01). Chin Sci Bull 48, 941–948.[CrossRef]
    [Google Scholar]
  11. Rota, P. A., Oberste, M. S., Monroe, S. S. & 32 other authors ( 2003;). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399.[CrossRef]
    [Google Scholar]
  12. WHO ( 2003a;). Severe acute respiratory syndrome (SARS) – multi-country outbreak – update 15. http://www.who.int/csr/don/2003_ 03_31/en/
  13. WHO ( 2003b;). Summary table of SARS cases by country, 1 November 2002 – 7 August 2003. http://www.who.int/csr/sars/country/en/ country2003_08_15.pdf
  14. WHO ( 2003c;). Severe acute respiratory syndrome (SARS). Wkly Epidemiol Rec 78, 181–183.
  15. WHO ( 2003d;). Preliminary clinical description of severe acute respiratory syndrome. http://www.who.int/csr/sars/clinical/en/
  16. WHO ( 2003e;). Sampling for severe acute respiratory syndrome (SARS) diagnostic tests. http://www.who.int/csr/sars/sampling/en/
  17. WHO ( 2003f;). Case definitions for surveillance of severe acute respiratory syndrome (SARS). http://www.who.int/csr/sars/casedefinition/en/

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error